| abstract |
Anthranylamidpyridinamides are described as VEGFR-2 and VEGFR-3 inhibitors, their production and use as medicaments for the treatment of diseases which are triggered by persistent angiogenesis. The compounds of the invention can be used as or in psoriasis, Kaposis sarcoma, restenosis, such as. B. Stent-induced restenosis, endometriosis, Crohn's disease, Hodgkins disease, leukemia, arthritis, such as rheumatoid arthritis, hemangioma, angiofribroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic malignant nephropathy, malignant nephropathy , Transplant rejection and glomerulopathy, fibrotic diseases such as cirrhosis of the liver, mesangial cell proliferative diseases, atherosclerosis, injuries to the nerve tissue and inhibition of reocclusion of vessels after balloon catheter treatment, in vascular prosthetics or after the insertion of mechanical devices for keeping vessels open, such as, for. B. stents, as immunosuppressants, as support for scar-free wound healing, age spots and contact dermatitis. The compounds according to the invention can also be used as VEGFR-3 inhibitors in lymphangiogenesis in the case of hyper- and dysplastic changes in the lymphatic system. |